Spanish pharmaceutical company PharmaMar said on 26 January 2021 that that peer reviewed journal, Science, has published a paper that confirms that the company's drug Plitidepsin has a "potent preclinical efficacy" against COVID-19, Reuters news agency reported on Tuesday.
In a statement, PharmaMar said the Science paper reported that a study carried out in vitro and in vivo by a team of scientists in New York, San Francisco and Paris showed the drug leads to a reduction of viral replication, resulting in a 99% reduction of viral loads in the lungs of Plitidepsin-treated animals.
PharmaMar quoted Science as saying: "We believe that our data and the initial positive results from PharmaMar's clinical trial suggests that Plitidepsin should be strongly considered for expanded clinical trials for the treatment of COVID-19."
Reportedly, Plitidepsin, already authorised in some markets to treat tumours, blocks a protein associated with the COVID-19 virus. Toxicity of the drug is well known and the doses used in COVID-19 trials are well tolerated in humans.
PharmaMar added that it was in talks with various regulatory agencies to start Phase III trials.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval